Vera Therapeutics, Inc. (VERA): R&D Expense
$215.26M
Year ended 2025-12-31
$261.87M
Trailing 12 months to 2026-06-30
+46.1%
3-year compound annual growth
+36.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $215.26M | +70.6% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $126.17M | +61.3% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $78.22M | +13.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $68.99M | +206.9% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $22.48M | -50.3% | 2023-03-28, From 2021-01-01 |
| 2020-12-31 | $45.21M | n/a | 2022-03-28, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $215.26M | +70.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $537.67M | +256.6% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $32.51M | +56.4% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $285.20M | -18.1% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $240.28M | +38.9% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $344.95M | +239.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
Compare VERA, KURA, SDGR, SMMT side by side · Screen every company in Pharmaceutical Preparations ↗